| EXAMINATION | - TANAKA A. ET AL., "Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractor to UDCA", J. GASTROENTEROL., (2015), vol. 50, pages 675 - 682 | - |
| OPPOSITION | - Avegail Flores, Marlyn J. Mayo , "primary biliary cirrhosis in 2014", Current Opinion in Gastroenterology, (20140101), vol. 30, pages 245 - 252, XP055953918 | - |
| OPPOSITION | - Frans J.C. Cueperus, Emina Halibasic , Michael Trauner , "fibrate treatment for primary cirrhosis", Current Opinion in Gastroenterology, (20140101), vol. 30, pages 279 - 286, XP055953910 | - |
| OPPOSITION | - Kidst K. Yiman, "obeticholic acid for the treatment of primary biliary cirrhosis", Expert Opinion on Orphan Drugs, (20140101), vol. 2, no. 12, pages 1351 - 1358, XP055953902 | - |
| OPPOSITION | - Raoul Poupon, "Evidence based treatment of primary biliary cirrhosis", Digestive Diseases, (20140101), vol. 32, pages 626 - 630, XP055953905 | - |
| OPPOSITION | - Sorokin, A. Brown, J.L. Thompson, P.D., "Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20071006), vol. 194, no. 2, doi:10.1016/j.atherosclerosis.2006.11.036, ISSN 0021-9150, pages 293 - 299, XP022288376 | |
| OPPOSITION | - Philippe Lefebvre, Bertrand Cariou, Fleur Lien, Folkert Kuipers, Bart Staels, "Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation", PHYSIOLOGICAL REVIEWS, AMERICAN PHYSIOLOGICAL SOCIETY, US, US , (20090101), vol. 89, no. 1, doi:10.1152/physrev.00010.2008, ISSN 0031-9333, pages 147 - 191, XP055489509 | |
| SEARCH | - CIPRIANI SABRINA ET AL, "FXR Activation Reverses Insulin Resistance and Protects Against NASH Development", GASTROENTEROLOGY, & DIGESTIVE DISEASE WEEK/110TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; CHICAGO, IL, USA; MAY 30 -JUNE 04, 2009, (200905), vol. 136, no. 5, Suppl. 1, ISSN 0016-5085, pages A420 - A421, XP002784423 [Y] 1-15 * abstract * | - |
| SEARCH | - TREBICKA J ET AL, "Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 53, no. 4, ISSN 0168-8278, (20101001), pages 702 - 712, (20100618), XP027241358 [Y] 1-15 * page 702, abstract * | - |
| SEARCH | - MOHAMED DOAA I ET AL, "Fenofibrate A peroxisome proliferator activated receptor-[alpha] agonist treatment ameliorates Concanavalin A-induced hepatitis in", EUROPEAN JOURNAL OF PHARMACOLOGY, (20131017), vol. 721, no. 1, doi:10.1016/J.EJPHAR.2013.09.058, ISSN 0014-2999, pages 35 - 42, XP028789364 [Y] 1-15 * page 35, abstract * | |
| SEARCH | - FIORUCCI ET AL, "Targeting farnesoid X receptor for liver and metabolic disorders", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, GB, (20070701), vol. 13, no. 7, doi:10.1016/J.MOLMED.2007.06.001, ISSN 1471-4914, pages 298 - 309, XP022142195 [Y] 1-15 * the whole document * | |
| SEARCH | - FIORUCCI S ET AL, "CROSS-TALK BETWEEN FARNESOID-X-RECEPTOR (FXR) AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA CONTRIBUTES TO THE ANTIFIBROTIC ACTIVITY OF FXR LIGANDS IN RODENT MODELS OF LIVER CIRRHOSIS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,, (20050624), vol. 315, no. 1, doi:10.1124/JPET.105.085597, ISSN 0022-3565, pages 58 - 68, XP008060972 [Y] 1-15 * page 58, abstract * | |
